全球研发 | 国际认可!复星医药自研创新药复迈宁获沙特突破性疗法认定

复星医药
Aug 18

近日,复星医药自主研发的创新药芦沃美替尼片(商品名:复迈宁®)获沙特食品药品监督管理局(SFDA)授予的突破性疗法认定,用于治疗朗格汉斯细胞组织细胞增生症(LCH)和组织细胞肿瘤成人患者适应症,标志着芦沃美替尼片将加速在沙特的临床注册和商业化进程。王兴利复星医药联席总裁、全球研发中心首席执行官“非常高兴芦沃美替尼片成人LCH适应症获沙特食品药品监督管理局突破性疗法认定,这不仅体现了复迈宁的临床价值...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10